SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Hammarström Per)
 

Sökning: WFRF:(Hammarström Per) > Amyloid fibril poly...

Amyloid fibril polymorphism: a challenge for molecular imaging and therapy

Fändrich, M. (författare)
Ulm Univ, Germany
Nyström, Sofie (författare)
Linköpings universitet,Kemi,Tekniska fakulteten
Nilsson, Peter (författare)
Linköpings universitet,Kemi,Tekniska fakulteten
visa fler...
Bockmann, A. (författare)
Univ Lyon, France
LeVine, H. III (författare)
Univ Kentucky, KY 40536 USA; Univ Kentucky, KY USA
Hammarström, Per (författare)
Linköpings universitet,Kemi,Tekniska fakulteten
visa färre...
 (creator_code:org_t)
2018-02-19
2018
Engelska.
Ingår i: Journal of Internal Medicine. - : WILEY. - 0954-6820 .- 1365-2796. ; 283:3, s. 218-237
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • The accumulation of misfolded proteins (MPs), both unique and common, for different diseases is central for many chronic degenerative diseases. In certain patients, MP accumulation is systemic (e.g. TTR amyloid), and in others, this is localized to a specific cell type (e.g. Alzheimers disease). In neurodegenerative diseases, NDs, it is noticeable that the accumulation of MP progressively spreads throughout the nervous system. Our main hypothesis of this article is that MPs are not only markers but also active carriers of pathogenicity. Here, we discuss studies from comprehensive molecular approaches aimed at understanding MP conformational variations (polymorphism) and their bearing on spreading of MPs, MP toxicity, as well as MP targeting in imaging and therapy. Neurodegenerative disease (ND) represents a major and growing societal challenge, with millions of people worldwide suffering from Alzheimers or Parkinsons diseases alone. For all NDs, current treatment is palliative without addressing the primary cause and is not curative. Over recent years, particularly the shape-shifting properties of misfolded proteins and their spreading pathways have been intensively researched. The difficulty in addressing ND has prompted most major pharma companies to severely downsize their nervous system disorder research. Increased academic research is pivotal for filling this void and to translate basic research into tools for medical professionals. Recent discoveries of targeting drug design against MPs and improved model systems to study structure, pathology spreading and toxicity strongly encourage future studies along these lines to provide an opportunity for selective imaging, prognostic diagnosis and therapy.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Medicinska och farmaceutiska grundvetenskaper -- Neurovetenskaper (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Basic Medicine -- Neurosciences (hsv//eng)

Nyckelord

Alzheimers disease; amyloidosis; biochemistry; chronic diseases; pathology

Publikations- och innehållstyp

ref (ämneskategori)
art (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Sök utanför SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy